Navigation Links
Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
Date:10/16/2007

antisense drugs for the treatment of asthma and other respiratory conditions. More information on Altair is available at http://www.altairtherapeutics.com.

About ISIS 369645

ISIS 369645 is an antisense drug that acts as an inhibitor of the IL-4/IL-13 cytokine signaling pathways, which play an important role in asthma. In preclinical studies, inhibition of IL-4/IL-13 signaling pathways reduced lung cytokine production, inflammation, and airway hyper-responsiveness and when delivered by inhalation can rapidly distribute to target tissues at therapeutic doses.

About Thomas, McNerney & Partners

Thomas, McNerney & Partners, LLC, is a health care private equity firm that invests in life science and medical technology companies. Employing a multi-stage investment approach, Thomas, McNerney & Partners has just under $600 million in assets under management and provides seed and early stage funding to help entrepreneurs launch companies, as well as growth capital to emerging companies for furthering clinical development or for expansion of product commercialization. For more information, please visit http://www.tm-partners.com .

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licens
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Jellyfish partners for sales tracking technology
4. GE Healthcare partners with UNC on breast cancer imaging research
5. Manufacturing partnership will move into biotech and biomedical spaces
6. Fergus joins Baird Venture Partners, Caden Bio
7. Avolte Venture Partners reaches capital goal
8. NimbleGen partners with UK biotech firm
9. Big pharma seeks Wisconsin biotech partnerships
10. Thompson in partnership to build ethanol plant
11. Johnson Controls partners on car satellite linkup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Madison Gas & Electric has released its 2005 ... expanded and updated listings covering 394 organizations. , ,The ... publication, offers an overview of the high-tech firms, professional ... programs in Dane County, as well as an array ...
... Placements: The mechanics of raising capital for your business ... things a company should do is prepare a business ... the private placement memorandum (PPM), the disclosure document that ... company has a good draft of the business plan ...
... the first in a new WTN series that will follow ... next few weeks, we'll focus on finalists in the Governor's ... inordinate amounts of it on rote procedures. For Milwaukee-area general ... five minutes to mark tissue cut out during cancer surgeries ...
Cached Biology Technology:2005 Madison-area tech directory includes more companies, resources 22005 Madison-area tech directory includes more companies, resources 3Due diligence and corporate clean-up 2Due diligence and corporate clean-up 3Due diligence and corporate clean-up 4Vector Surgical hopes to turn frustration into faster surgeries 2Vector Surgical hopes to turn frustration into faster surgeries 3
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... coactivators control the process by which a single gene ... called alternative splicing, said Baylor College of Medicine researchers ... the journal Molecular Cell. "A major question in biology ... at least 120,000 proteins," said Dr. Bert O'Malley, chair ...
... Starvation, malnutrition and re-feeding can have deadly consequences for ... frog. , PhD student Rebecca Cramp from The University ... can't digest food after long periods of starvation, the ... percent more effectively after 3 months without food, than ...
... immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) ... and non-Hodgkin lymphoma, according to a new study ... of the National Cancer Institute. , Studies of ... increased risks of several cancers, including Kaposi sarcoma, ...
Cached Biology News:Controlling protein diversity 2A frog's life is food for thought 2A frog's life is food for thought 3Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2
Evolutionarily conserved signaling intermediate in Toll pathway...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Biology Products: